US 12,305,205 B2
AprL-clade protease variants and uses thereof
David A. Estell, San Mateo, CA (US); Frits Goedegebuur, Vlaardingen (NL); Marc Anton Bernhard Kolkman, Oegstgeest (NL); Rie Mejldal, Ostbirk (DK); Katherine Augustyn, San Francisco, CA (US); Lilia Maria Babe, Emerald Hills, CA (US); Richard R Bott, Kirkland, WA (US); Jian Yao, Sunnyvale, CA (US); and Roopa Santosh Ghirnikar, Sunnyvale, CA (US)
Assigned to Danisco US Inc., Palo Alto, CA (US)
Filed by DANISCO US INC, Palo Alto, CA (US)
Filed on Sep. 30, 2022, as Appl. No. 17/957,218.
Application 17/957,218 is a division of application No. 16/720,106, filed on Dec. 19, 2019, granted, now 11,473,075.
Application 16/720,106 is a continuation of application No. 15/572,882, abandoned, previously published as PCT/US2016/032514, filed on May 13, 2016.
Claims priority of provisional application 62/161,077, filed on May 13, 2015.
Prior Publication US 2024/0301383 A1, Sep. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/54 (2006.01); C11D 3/386 (2006.01)
CPC C12N 9/54 (2013.01) [C11D 3/386 (2013.01); C11D 3/38681 (2013.01); C12Y 304/21062 (2013.01)] 15 Claims
 
1. A variant subtilisin enzyme or an active fragment thereof comprising one or more amino acid modification to a parent AprL-clade subtilisin enzyme, wherein the modification is selected from the group consisting of G165A, G165E, G165Q, G165R, and G165S, wherein the amino acid positions of the subtilisin variant are numbered by correspondence with the amino acid sequence of Bacillus sp. AprL subtilisin set forth in SEQ ID NO:2, wherein said variant has an improved stability when compared to the parent AprL-clade subtilisin enzyme, and wherein said variant has at least 85% amino acid sequence identity to the amino acid sequence of SEQ ID NO:2.